Clinical applications involving CNS gene transfer

Advances in Genetics

Volumn 87, Issue , 2014, Pages 71-124

  Kantor, Boris ^a   McCown, Thomas ^b   Leone, Paola ^c   Gray, Steven J ^b  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c ROWAN UNIVERSITY   (United States)

Author keywords

AAV; Canavan disease; Clinical trial; CNS; Gene therapy; Lentivirus; Parkinson's disease; Retrovirus; Vector

Indexed keywords

CENTRAL NERVOUS SYSTEM DISEASES; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; LENTIVIRINAE; PROCEDURES;

CENTRAL NERVOUS SYSTEM DISEASES; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LENTIVIRUS;

EID: 84908413407     PISSN: 00652660     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800149-3.00002-0     Document Type: Chapter

References (211)

1. Adachi M., Schneck L., Cara J., Volk B.W. Spongy degeneration of the central nervous system (van Bogaert and Bertrand type; Canavan's disease). A review. Human Pathology 1973, 4(3):331-347. [Review].
2. Ahmed S.S., Li H., Cao C., Sikoglu E.M., Denninger A.R., Su Q., et al. A single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS gene therapy in canavan mice. Molecular Therapy 2013, 21(12):2136-2147. [Research Support, N.I.H., Extramural, Research Support, Non-U.S. Govt.]. 10.1038/mt.2013.138.
3. Aiuti A., Biasco L., Scaramuzza S., Ferrua F., Cicalese M.P., Baricordi C., et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 2013, 341(6148):1233151.
4. + cells differentiate into microglia and express recombinant therapeutic protein. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(10):3557-3562. [Research Support, Non-U.S. Govt]. 10.1073/pnas.0306431101.
5. Assadi M., Janson C., Wang D.J., Goldfarb O., Suri N., Bilaniuk L., et al. Lithium citrate reduces excessive intra-cerebral N-acetyl aspartate in Canavan disease. European Journal of Paediatric Neurology 2010, 14(4):354-359. 10.1016/j.ejpn.2009.11.006.
6. Azzouz M., Martin-Rendon E., Barber R.D., Mitrophanous K.A., Carter E.E., Rohll J.B., et al. Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic l-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. Journal of Neuroscience 2002, 22(23):10302-10312.
7. Azzouz M., Ralph G.S., Storkebaum E., Walmsley L.E., Mitrophanous K.A., Kingsman S.M., et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004, 429(6990):413-417. 10.1038/nature02544.
8. Azzouz M., Ralph S., Wong L.F., Day D., Askham Z., Barber R.D., et al. Neuroprotection in a rat Parkinson model by GDNF gene therapy using EIAV vector. Neuroreport 2004, 15(6):985-990.
9. Baekelandt V., Claeys A., Eggermont K., Lauwers E., De Strooper B., Nuttin B., et al. Characterization of lentiviral vector-mediated gene transfer in adult mouse brain. Human Gene Therapy 2002, 13(7):841-853.
10. Bankiewicz K.S., Daadi M., Pivirotto P., Bringas J., Sanftner L., Cunningham J., et al. Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys. Experimental Neurology 2006, 197(2):363-372. [Comparative Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Govt.]. 10.1016/j.expneurol.2005.10.022.
11. Bankiewicz K.S., Eberling J.L., Kohutnicka M., Jagust W., Pivirotto P., Bringas J., et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Experimental Neurology 2000, 164(1):2-14.
12. Barker R.A. Continuing trials of GDNF in Parkinson's disease. Lancet Neurology 2006, 5(4):285-286.
13. Baslow M.H. Molecular water pumps and the aetiology of Canavan disease: a case of the sorcerer's apprentice. Journal of Inherited Metabolic Disease 1999, 22(2):99-101. [Review].
14. Baslow M.H., Guilfoyle D.N. Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease?. Neurochemical Research 2009, 34(9):1523-1534. 10.1007/s11064-009-9958-z.
15. Baslow M.H., Guilfoyle D.N. Canavan disease, a rare early-onset human spongiform leukodystrophy: insights into its genesis and possible clinical interventions. Biochimie 2013, 95(4):946-956. 10.1016/j.biochi.2012.10.023.
16. Baum C., Fehse B. Mutagenesis by retroviral transgene insertion: risk assessment and potential alternatives. Current Opinion Molecular Therapy 2003, 5(5):458-462.
17. Bayer M., Kantor B., Cockrell A., Ma H., Zeithaml B., Li X., et al. A large U3 deletion causes increased in vivo expression from a nonintegrating lentiviral vector. Molecular Therapy 2008, 16(12):1968-1976.
18. + cells from adrenoleukodystrophy patients with HIV-derived vector mediate long-term engraftment of NOD/SCID mice. Molecular Therapy 2003, 7(3):317-324.
19. Bensadoun J.C., de Almeida L.P., Dreano M., Aebischer P., Deglon N. Neuroprotective effect of interleukin-6 and IL6/IL6R chimera in the quinolinic acid rat model of Huntington's syndrome. European Journal of Neuroscience 2001, 14(11):1753-1761.
20. Bessis N., GarciaCozar F.J., Boissier M.C. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Therapy 2004, 11(Suppl. 1):S10-S17.
21. Biffi A., Aubourg P., Cartier N. Gene therapy for leukodystrophies. Human Molecular Genetics 2011, 20(R1):R42-R53.
22. Biffi A., Capotondo A., Fasano S., del Carro U., Marchesini S., Azuma H., et al. Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. Journal of Clinical Investigation 2006, 116(11):3070-3082.
23. Biffi A., De Palma M., Quattrini A., Del Carro U., Amadio S., Visigalli I., et al. Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. Journal of Clinical Investigation 2004, 113(8):1118-1129.
24. Biffi A., Montini E., Lorioli L., Cesani M., Fumagalli F., Plati T., et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013, 341(6148):1233158.
25. Blaese R.M., Culver K.W., Miller A.D., Carter C.S., Fleisher T., Clerici M., et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995, 270(5235):475-480.
26. Blomer U., Naldini L., Kafri T., Trono D., Verma I.M., Gage F.H. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. Journal of Virology 1997, 71(9):6641-6649.
27. Boelens J.J., Prasad V.K., Tolar J., Wynn R.F., Peters C. Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders. Pediatric Clinics of North America 2010, 57(1):123-145.
28. Bosch A., Perret E., Desmaris N., Trono D., Heard J.M. Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer. Human Gene Therapy 2000, 11(8):1139-1150.
29. Bosticardo M., Marangoni F., Aiuti A., Villa A., Grazia Roncarolo M. Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood 2009, 113(25):6288-6295.
30. Boustany R.M. Lysosomal storage diseases-the horizon expands. Nature Reviews Neurology 2013, 9(10):583-598.
31. Boztug K., Schmidt M., Schwarzer A., Banerjee P.P., Diez I.A., Dewey R.A., et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. New England Journal of Medicine 2010, 363(20):1918-1927.
32. Bruni S., Loschi L., Incerti C., Gabrielli O., Coppa G.V. Update on treatment of lysosomal storage diseases. Acta Myologica 2007, 26(1):87-92.
33. Buchow H.D., Tschachler E., Gallo R.C., Reitz M. HIV-I replication requires an intact integrase reading frame. Hematology and Blood Transfusion 1989, 32:402-405.
34. Burri R., Steffen C., Herschkowitz N. N-acetyl-L-aspartate is a major source of acetyl groups for lipid synthesis during rat brain development. Developmental Neuroscience 1991, 13(6):403-411. [Research Support, Non-U.S. Govt.].
35. Cabrera-Salazar M.A., Roskelley E.M., Bu J., Hodges B.L., Yew N., Dodge J.C., et al. Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease. Molecular Therapy 2007, 15(10):1782-1788. [Research Support, N.I.H., Extramural, Research Support, Non-U.S. Govt.]. 10.1038/sj.mt.6300249.
36. Canavan M.M. Schilder's encephalitis periaxialis diffusa. Archives of Neurology & Psychiatry 1931, 25:299-308.
37. Canivet M., Hoffman A.D., Hardy D., Sernatinger J., Levy J.A. Replication of HIV-1 in a wide variety of animal cells following phenotypic mixing with murine retroviruses. Virology 1990, 178(2):543-551.
38. Cannon J.R., Sew T., Montero L., Burton E.A., Greenamyre J.T. Pseudotype-dependent lentiviral transduction of astrocytes or neurons in the rat substantia nigra. Experimental Neurology 2011, 228(1):41-52. [Comparative Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Govt. Research Support, U.S. Govt., Non-P.H.S.]. 10.1016/j.expneurol.2010.10.016.
39. Carter B.J. Adeno-associated virus vectors in clinical trials. [Review]. Human Gene Therapy 2005, 16(5):541-550. 10.1089/hum.2005.16.541.
40. Cartier N., Hacein-Bey-Abina S., Bartholomae C.C., Veres G., Schmidt M., Kutschera I., et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009, 326(5954):818-823. 10.1126/science.1171242.
41. Cavazzana-Calvo M., Hacein-Bey S., de Saint Basile G., Gross F., Yvon E., Nusbaum P., et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000, 288(5466):669-672.
42. Cavazzana-Calvo M., Payen E., Negre O., Wang G., Hehir K., Fusil F., et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010, 467(7313):318-322.
43. Chesebro B., Wehrly K., Maury W. Differential expression in human and mouse cells of human immunodeficiency virus pseudotyped by murine retroviruses. Journal of Virology 1990, 64(9):4553-4557.
44. Christine C.W., Starr P.A., Larson P.S., Eberling J.L., Jagust W.J., Hawkins R.A., et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 2009, 73(20):1662-1669. 10.1212/WNL.0b013e3181c29356.
45. Ciesielska A., Hadaczek P., Mittermeyer G., Zhou S., Wright J.F., Bankiewicz K.S., et al. Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. Molecular Therapy 2013, 21(1):158-166. [Research Support, N.I.H., Extramural]. 10.1038/mt.2012.167.
46. Clarke J.T., Iwanochko R.M. Enzyme replacement therapy of Fabry disease. Molecular Neurobiology 2005, 32(1):43-50.
47. Cline M.J. Perspectives for gene therapy: inserting new genetic information into mammalian cells by physical techniques and viral vectors. Pharmacology & Therapeutics 1985, 29(1):69-92.
48. Cockrell A.S., Kafri T. Gene delivery by lentivirus vectors. Molecular Biotechnology 2007, 36(3):184-204.
49. Coffin J.M., Hughes S.H., Varmus H.E. The interactions of retroviruses and their hosts 1997.
50. Colicelli J., Goff S.P. Mutants and pseudorevertants of Moloney murine leukemia virus with alterations at the integration site. Cell 1985, 42(2):573-580.
51. Colicelli J., Goff S.P. Sequence and spacing requirements of a retrovirus integration site. Journal of Molecular Biology 1988, 199(1):47-59.
52. Coney S. Gene trial causes ethical storm in New Zealand. Lancet 1996, 347(9017):1759. [News].
53. Consiglio A., Gritti A., Dolcetta D., Follenzi A., Bordignon C., Gage F.H., et al. Robust in vivo gene transfer into adult mammalian neural stem cells by lentiviral vectors. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(41):14835-14840.
54. Consiglio A., Quattrini A., Martino S., Bensadoun J.C., Dolcetta D., Trojani A., et al. In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice. Nature Medicine 2001, 7(3):310-316.
55. Conzelmann K.K., Cox J.H., Schneider L.G., Thiel H.J. Molecular cloning and complete nucleotide sequence of the attenuated rabies virus SAD B19. Virology 1990, 175(2):485-499.
56. Craigie R., Fujiwara T., Bushman F. The IN protein of Moloney murine leukemia virus processes the viral DNA ends and accomplishes their integration in vitro. Cell 1990, 62(4):829-837.
57. Cronin J., Zhang X.Y., Reiser J. Altering the tropism of lentiviral vectors through pseudotyping. Current Gene Therapy 2005, 5(4):387-398.
58. Dayton E.T., Powell D.M., Dayton A.I. Functional analysis of CAR, the target sequence for the Rev protein of HIV-1. Science 1989, 246(4937):1625-1629.
59. de Almeida L.P., Zala D., Aebischer P., Deglon N. Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease. Neurobiology of Disease 2001, 8(3):433-446.
60. Desmaris N., Bosch A., Salaun C., Petit C., Prevost M.C., Tordo N., et al. Production and neurotropism of lentivirus vectors pseudotyped with lyssavirus envelope glycoproteins. Molecular Therapy 2001, 4(2):149-156.
61. Dirren E., Towne C.L., Setola V., Redmond D.E., Schneider B.L., Aebischer P. Intracerebroventricular injection of adeno-associated virus 6 and 9 vectors for cell type-specific transgene expression in the spinal cord. Human Gene Therapy 2014, 25(2):109-120. [Research Support, Non-U.S. Govt.]. 10.1089/hum.2013.021.
62. Dodart J.C., Marr R.A., Koistinaho M., Gregersen B.M., Malkani S., Verma I.M., et al. Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(4):1211-1216.
63. Dull T., Zufferey R., Kelly M., Mandel R.J., Nguyen M., Trono D., et al. A third-generation lentivirus vector with a conditional packaging system. Journal of Virology 1998, 72(11):8463-8471.
64. Duque S., Joussemet B., Rissviere C., Marais T., Dubreil L., Douar A.M., Barkats M. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Molecular Therapy 2009, 17(7):1187-1196. 10.1038/mt.2009.71.
65. During M.J. Gene trial in New Zealand. Lancet 1996, 348(9027):618. [Letter]. 10.1016/S0140-6736(05)64836-2.
66. Emerman M., Vazeux R., Peden K. The rev gene product of the human immunodeficiency virus affects envelope-specific RNA localization. Cell 1989, 57(7):1155-1165.
67. Emi N., Friedmann T., Yee J.K. Pseudotype formation of murine leukemia virus with the G protein of vesicular stomatitis virus. Journal of Virology 1991, 65(3):1202-1207. [Research Support, Non-U.S. Govt. Research Support, U.S. Govt., P.H.S.].
68. Escolar M.L., Poe M.D., Provenzale J.M., Richards K.C., Allison J., Wood S., et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. New England Journal of Medicine 2005, 352(20):2069-2081. [Clinical Trial, Research Support, Non-U.S. Govt. Research Support, U.S. Govt., P.H.S.]. 10.1056/NEJMoa042604.
69. Evans J.R., Barker R.A. Neurotrophic factors as a therapeutic target for Parkinson's disease. Expert Opinion on Therapeutic Targets 2008, 12(4):437-447.
70. Federici T., Taub J.S., Baum G.R., Gray S.J., Grieger J.C., Matthews K.A., et al. Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. Gene Therapy 2012, 19(8):852-859. 10.1038/gt.2011.130.
71. Feng L.R., Maguire-Zeiss K.A. Gene therapy in Parkinson's disease: rationale and current status. CNS Drugs 2010, 24(3):177-192.
72. Ferreira J.J., Guedes L.C., Rosa M.M., Coelho M., van Doeselaar M., Schweiger D., et al. High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal. Movement Disorders 2007, 22(8):1194-1201.
73. + toxicity in models of human neurons. European Journal of Neuroscience 2008, 28(12):2459-2473.
74. +) toxicity and reduces dopamine transport. Journal of Neuroscience Research 2007, 85(2):351-363.
75. Foust K.D., Nurre E., Montgomery C.L., Hernandez A., Chan C.M., Kaspar B.K. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nature Biotechnology 2009, 27(1):59-65.
76. Foust K.D., Wang X., McGovern V.L., Braun L., Bevan A.K., Haidet A.M., et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nature Biotechnology 2010, 28(3):271-274. 10.1038/nbt.1610.
77. Francis J.S., Markov V., Leone P. Dietary triheptanoin rescues oligodendrocyte loss, dysmyelination and motor function in the nur7 mouse model of Canavan disease. [Research Support, Non-U.S. Gov't]. Journal of Inherited Metabolic Disease 2014, 37(3):369-381. 10.1007/s10545-013-9663-6.
78. Francis J.S., Olariu A., McPhee S.W., Leone P. Novel role for aspartoacylase in regulation of BDNF and timing of postnatal oligodendrogenesis. Journal of Neuroscience Research 2006, 84(1):151-169. [Comparative Study, Research Support, Non-U.S. Govt.]. 10.1002/jnr.20866.
79. Francis J.S., Strande L., Markov V., Leone P. Aspartoacylase supports oxidative energy metabolism during myelination. Journal of Cerebral Blood Flow & Metabolism 2012, 32(9):1725-1736. [Research Support, Non-U.S. Govt.]. 10.1038/jcbfm.2012.66.
80. Friedmann T. The future for gene therapy-a reevaluation. Annals of the New York Academy of Sciences 1976, 265:141-152.
81. Fu H., Dirosario J., Killedar S., Zaraspe K., McCarty D.M. Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Molecular Therapy 2011, 19(6):1025-1033.
82. Gadalla K.K., Bailey M.E., Spike R.C., Ross P.D., Woodard K.T., Kalburgi S.N., et al. Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice. Molecular Therapy 2013, 21(1):18-30. [Research Support, Non-U.S. Govt.]. 10.1038/mt.2012.200.
83. Gambetti P., Mellman W.J., Gonatas N.K. Familial spongy degeneration of the central nervous system (Van Bogaert-Bertrand disease). An ultrastructural study. Acta Neuropathology 1969, 12(2):103-115.
84. Gao X., Huang L. Potentiation of cationic liposome-mediated gene delivery by polycations. Biochemistry 1996, 35(3):1027-1036. [Research Support, U.S. Govt., P.H.S.]. 10.1021/bi952436a.
85. Gao G., Vandenberghe L.H., Wilson J.M. New recombinant serotypes of AAV vectors. Current Gene Therapy 2005, 5(3):285-297.
86. Garg S.K., Lioy D.T., Cheval H., McGann J.C., Bissonnette J.M., Murtha M.J., et al. Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome. Journal of Neuroscience 2013, 33(34):13612-13620. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Govt.]. 10.1523/JNEUROSCI.1854-13.2013.
87. Gasmi M., Brandon E.P., Herzog C.D., Wilson A., Bishop K.M., Hofer E.K., et al. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiology of Disease 2007, 27(1):67-76. 10.1016/j.nbd.2007.04.003.
88. Gasmi M., Herzog C.D., Brandon E.P., Cunningham J.J., Ramirez G.A., Ketchum E.T., et al. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Molecular Therapy 2007, 15(1):62-68. 10.1038/sj.mt.6300010.
89. Gaspar H.B., Parsley K.L., Howe S., King D., Gilmour K.C., Sinclair J., et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004, 364(9452):2181-2187.
90. Ginn S.L., Alexander I.E., Edelstein M.L., Abedi M.R., Wixon J. Gene therapy clinical trials worldwide to 2012-an update. Journal of Gene Medicine 2013, 15(2):65-77. [Research Support, Non-U.S. Govt., Review]. 10.1002/jgm.2698.
91. Goncalves M.A. Adeno-associated virus: from defective virus to effective vector. Virology Journal 2005, 2:43.
92. Gray S.J., Blake B.L., Criswell H.E., Nicolson S.C., Samulski R.J., McCown T.J. Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Molecular Therapy 2010, 18(3):570-578. 10.1038/mt.2009.292.
93. Gray S.J., Matagne V., Bachaboina L., Yadav S., Ojeda S.R., Samulski R.J. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Molecular Therapy 2011, 19(6):1058-1069.
94. Gray S.J., Nagabhushan Kalburgi S., McCown T.J., Jude Samulski R. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Therapy 2013, 20(4):450-459. 10.1038/gt.2012.101.
95. Gray S.J., Woodard K.T., Samulski R.J. Viral vectors and delivery strategies for CNS gene therapy. Therapeutic Delivery 2010, 1(4):517-534. [review].
96. Grosset D. Parkinson's disease and related disorders-XVIII WFN World Congress. IDrugs 2010, 13(2):82-84.
97. Haberman R.P., Samulski R.J., McCown T.J. Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nature Medicine 2003, 9(8):1076-1080. 10.1038/nm901.
98. Hacein-Bey-Abina S., von Kalle C., Schmidt M., Le Deist F., Wulffraat N., McIntyre E., et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. New England Journal of Medicine 2003, 348(3):255-256.
99. Hacein-Bey-Abina S., von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., Cavazzana-Calvo M. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302(5644):415-419.
100. Hackett N.R., Redmond D.E., Sondhi D., Giannaris E.L., Vassallo E., Stratton J., et al. Safety of direct administration of AAV2(CU)hCLN2, a candidate treatment for the central nervous system manifestations of late infantile neuronal ceroid lipofuscinosis, to the brain of rats and nonhuman primates. Human Gene Therapy 2005, 16(12):1484-1503. [Research Support, N.I.H., Extramural, Research Support, Non-U.S. Govt.]. 10.1089/hum.2005.16.1484.
101. Hadaczek P., Eberling J.L., Pivirotto P., Bringas J., Forsayeth J., Bankiewicz K.S. Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Molecular Therapy 2010, 18(8):1458-1461. [Research Support, N.I.H., Extramural]. 10.1038/mt.2010.106.
102. Hadzopoulou-Cladaras M., Felber B.K., Cladaras C., Athanassopoulos A., Tse A., Pavlakis G.N. The rev (trs/art) protein of human immunodeficiency virus type 1 affects viral mRNA and protein expression via a cis-acting sequence in the env region. Journal of Virology 1989, 63(3):1265-1274.
103. Hagenfeldt L., Bollgren I., Venizelos N. N-acetylaspartic aciduria due to aspartoacylase deficiency-a new aetiology of childhood leukodystrophy. Journal of Inherited Metabolic Disease 1987, 10(2):135-141. [Case Reports].
104. Hansen J., Schulze T., Mellert W., Moelling K. Identification and characterization of HIV-specific RNase H by monoclonal antibody. EMBO Journal 1988, 7(1):239-243.
105. Haurigot V., Marco S., Ribera A., Garcia M., Ruzo A., Villacampa P., Bosch F. Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. Journal of Clinical Investigation 2013, 123(8):3254-3271. 10.1172/JCI66778.
106. Hematti P., Hong B.K., Ferguson C., Adler R., Hanawa H., Sellers S., et al. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biology 2004, 2(12):e423.
107. Herzog C.D., Brown L., Kruegel B.R., Wilson A., Tansey M.G., Gage F.H., et al. Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120). Neurobiology of Disease 2013, 58:38-48. 10.1016/j.nbd.2013.04.011.
108. Hwu W.L., Muramatsu S., Tseng S.H., Tzen K.Y., Lee N.C., Chien Y.H., et al. Gene therapy for aromatic l-amino acid decarboxylase deficiency. Science Translational Medicine 2012, 4(134):134ra161. [Clinical Trial Research Support, Non-U.S. Govt.]. 10.1126/scitranslmed.3003640.
109. Iwakuma T., Cui Y., Chang L.J. Self-inactivating lentiviral vectors with U3 and U5 modifications. Virology 1999, 261(1):120-132.
110. Jakobsson J., Ericson C., Jansson M., Bjork E., Lundberg C. Targeted transgene expression in rat brain using lentiviral vectors. Journal of Neuroscience Research 2003, 73(6):876-885.
111. Janson C.G., Assadi M., Francis J., Bilaniuk L., Shera D., Leone P. Lithium citrate for Canavan disease. Pediatric Neurology 2005, 33(4):235-243. [Case Reports]. 10.1016/j.pediatrneurol.2005.04.015.
112. Janson C.G., Kolodny E.H., Zeng B.J., Raghavan S., Pastores G., Torres P., et al. Mild-onset presentation of Canavan's disease associated with novel G212A point mutation in aspartoacylase gene. Annals of Neurology 2006, 59(2):428-431. [Case Reports, Comparative Study]. 10.1002/ana.20787.
113. Janson C., McPhee S., Bilaniuk L., Haselgrove J., Testaiuti M., Freese A., et al. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Human Gene Therapy 2002, 13(11):1391-1412. 10.1089/104303402760128612.
114. Janson C.G., McPhee S.W., Francis J., Shera D., Assadi M., Freese A., et al. Natural history of Canavan disease revealed by proton magnetic resonance spectroscopy (1H-MRS) and diffusion-weighted MRI. Neuropediatrics 2006, 37(4):209-221. [Comparative Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Govt.]. 10.1055/s-2006-924734.
115. Kafri T., van Praag H., Ouyang L., Gage F.H., Verma I.M. A packaging cell line for lentivirus vectors. Journal of Virology 1999, 73(1):576-584.
116. Kantor B., Bayer M., Ma H., Samulski J., Li C., McCown T., et al. Notable reduction in illegitimate integration mediated by a PPT-deleted, nonintegrating lentiviral vector. Molecular Therapy 2011, 19(3):547-556.
117. Kao J.H., Chen S.L., Ma H.I., Law P.Y., Tao P.L., Loh H.H. Intrathecal delivery of a mutant micro-opioid receptor activated by naloxone as a possible antinociceptive paradigm. Journal of Pharmacology and Experimental Therapeutics 2010, 334(3):739-745. 10.1124/jpet.109.165399.
118. Kaplitt M.G., Feigin A., Tang C., Fitzsimons H.L., Mattis P., Lawlor P.A., et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007, 369(9579):2097-2105. [Clinical Trial, Phase I, Research Support, Non-U.S. Govt.]. 10.1016/S0140-6736(07)60982-9.
119. Kaul R., Gao G.P., Balamurugan K., Matalon R. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease. Nature Genetics 1993, 5(2):118-123. [Research Support, Non-U.S. Govt.]. 10.1038/ng1093-118.
120. Kemp S., Berger J., Aubourg P. X-linked adrenoleukodystrophy: clinical, metabolic, genetic and pathophysiological aspects. Biochimica et Biophysica Acta 2012, 1822(9):1465-1474.
121. Klages N., Zufferey R., Trono D. A stable system for the high-titer production of multiply attenuated lentiviral vectors. Molecular Therapy 2000, 2(2):170-176.
122. Kumer S.C., Vrana K.E. Intricate regulation of tyrosine hydroxylase activity and gene expression. Journal of Neurochemistry 1996, 67(2):443-462.
123. Leavitt A.D., Rose R.B., Varmus H.E. Both substrate and target oligonucleotide sequences affect in vitro integration mediated by human immunodeficiency virus type 1 integrase protein produced in Saccharomyces cerevisiae. Journal of Virology 1992, 66(4):2359-2368.
124. Leone P., Janson C.G., Bilaniuk L., Wang Z., Sorgi F., Huang L., et al. Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease. Annals of Neurology 2000, 48(1):27-38. [Clinical Trial, Research Support, Non-U.S. Govt.].
125. Leone P., Janson C.G., McPhee S.J., During M.J. Global CNS gene transfer for a childhood neurogenetic enzyme deficiency: canavan disease. Current Opinion Molecular Therapy 1999, 1(4):487-492. [Review].
126. Leone P., Shera D., McPhee S.W., Francis J.S., Kolodny E.H., Bilaniuk L.T., et al. Long-term follow-up after gene therapy for canavan disease. Science Translational Medicine 2012, 4(165):165ra163. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Govt.]. 10.1126/scitranslmed.3003454.
127. Lewis P.F., Emerman M. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. Journal of Virology 1994, 68(1):510-516.
128. LeWitt P.A., Rezai A.R., Leehey M.A., Ojemann S.G., Flaherty A.W., Eskandar E.N., et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurology 2011, 10(4):309-319. [Randomized Controlled Trial, Research Support, Non-U.S. Govt.]. 10.1016/S1474-4422(11)70039-4.
129. Lo Bianco C., Schneider B.L., Bauer M., Sajadi A., Brice A., Iwatsubo T., et al. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(50):17510-17515.
130. Luo J., Kaplitt M.G., Fitzsimons H.L., Zuzga D.S., Liu Y., Oshinsky M.L., et al. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 2002, 298(5592):425-429. [Research Support, Non-U.S. Govt.]. 10.1126/science.1074549.
131. Madhavarao C.N., Arun P., Anikster Y., Mog S.R., Staretz-Chacham O., Moffett J.R., et al. Glyceryl triacetate for Canavan disease: a low-dose trial in infants and evaluation of a higher dose for toxicity in the tremor rat model. Journal of Inherited Metabolic Disease 2009, 32(5):640-650. [Clinical Trial, Research Support, N.I.H., Extramural Research Support, Non-U.S. Govt.]. 10.1007/s10545-009-1155-3.
132. Manno C.S., Pierce G.F., Arruda V.R., Glader B., Ragni M., Rasko J.J., et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nature Medicine 2006, 12(3):342-347.
133. Marks W.J., Bartus R.T., Siffert J., Davis C.S., Lozano A., Boulis N., et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurology 2010, 9(12):1164-1172. [Clinical Trial, Phase II, Multicenter Study, Randomized Controlled Trial]. 10.1016/S1474-4422(10)70254-4.
134. Marks W.J., Ostrem J.L., Verhagen L., Starr P.A., Larson P.S., Bakay R.A., et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurology 2008, 7(5):400-408.
135. Matalon R., Michals K., Kaul R. Canavan disease: from spongy degeneration to molecular analysis. Journal of Pediatrics 1995, 127(4):511-517. [Case Reports, Research Support, Non-U.S. Govt., Review].
136. Matalon R., Michals K., Sebesta D., Deanching M., Gashkoff P., Casanova J. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. American Journal of Medical Genetics 1988, 29(2):463-471. [Research Support, Non-U.S. Govt.]. 10.1002/ajmg.1320290234.
137. McCarty D.M., Fu H., Monahan P.E., Toulson C.E., Naik P., Samulski R.J. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Therapy 2003, 10(26):2112-2118.
138. McCarty D.M., Monahan P.E., Samulski R.J. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Therapy 2001, 8(16):1248-1254.
139. McCarty D.M., Young S.M., Samulski R.J. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annual Review of Genetics 2004, 38:819-845.
140. McPhee S.W., Francis J., Janson C.G., Serikawa T., Hyland K., Ong E.O., et al. Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease. Brain Research Molecular Brain Research 2005, 135(1-2):112-121. [Comparative Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Govt. Research Support, U.S. Govt., P.H.S.]. 10.1016/j.molbrainres.2004.12.007.
141. McPhee S.W., Janson C.G., Li C., Samulski R.J., Camp A.S., Francis J., et al. Immune responses to AAV in a phase I study for Canavan disease. Journal of Gene Medicine 2006, 8(5):577-588. 10.1002/jgm.885.
142. Melchiorri D., Pani L., Gasparini P., Cossu G., Ancans J., Borg J.J., et al. Regulatory evaluation of Glybera in Europe - two committees, one mission. Nature Review Drug Discovery 2013, 12(9):719. [Letter]. 10.1038/nrd3835-c1.
143. Miletic H., Fischer Y.H., Neumann H., Hans V., Stenzel W., Giroglou T., et al. Selective transduction of malignant glioma by lentiviral vectors pseudotyped with lymphocytic choriomeningitis virus glycoproteins. Human Gene Therapy 2004, 15(11):1091-1100.
144. Miller D.G., Adam M.A., Miller A.D. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990, 10(8):4239-4242.
145. Mingozzi F., High K.A. Immune responses to AAV in clinical trials. Curr Gene Ther 2007, 7(5):316-324.
146. Mittermeyer G., Christine C.W., Rosenbluth K.H., Baker S.L., Starr P., Larson P., et al. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Human Gene Therapy 2012, 23(4):377-381. [Clinical Trial, Phase I, Research Support, Non-U.S. Govt.]. 10.1089/hum.2011.220.
147. Miyoshi H., Blomer U., Takahashi M., Gage F.H., Verma I.M. Development of a self-inactivating lentivirus vector. Journal of Virology 1998, 72(10):8150-8157.
148. Mochizuki H., Schwartz J.P., Tanaka K., Brady R.O., Reiser J. High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells. Journal of Virology 1998, 72(11):8873-8883.
149. Modlich U., Navarro S., Zychlinski D., Maetzig T., Knoess S., Brugman M.H., et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Molecular Therapy 2009, 17(11):1919-1928.
150. Montini E., Cesana D., Schmidt M., Sanvito F., Bartholomae C.C., Ranzani M., et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. Journal of Clinical Investigation 2009, 119(4):964-975.
151. Montini E., Cesana D., Schmidt M., Sanvito F., Ponzoni M., Bartholomae C., et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nature Biotechnology 2006, 24(6):687-696.
152. Muramatsu S., Fujimoto K., Kato S., Mizukami H., Asari S., Ikeguchi K., et al. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Molecular Therapy 2010, 18(9):1731-1735. [Clinical Trial, Phase I, Research Support, Non-U.S. Govt.]. 10.1038/mt.2010.135.
153. Mussche S., Devreese B., Nagabhushan Kalburgi S., Bachaboina L., Fox J.C., Shih H.J., et al. Restoration of cytoskeleton homeostasis after gigaxonin gene transfer for giant axonal neuropathy. Human Gene Therapy 2013, 24(2):209-219. 10.1089/hum.2012.107.
154. Naldini L., Blomer U., Gage F.H., Trono D., Verma I.M. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proceedings of the National Academy of Sciences of the United States of America 1996, 93(21):11382-11388.
155. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272(5259):263-267.
156. Nathwani A.C., Tuddenham E.G., Rangarajan S., Rosales C., McIntosh J., Linch D.C., et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. New England Journal of Medicine 2011, 365(25):2357-2365. [Clinical Trial, Phase I, Clinical Trial, Phase II, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Govt.]. 10.1056/NEJMoa1108046.
157. Notarangelo L.D., Miao C.H., Ochs H.D. Wiskott-aldrich syndrome. Current Opinion in Hematology 2008, 15(1):30-36.
158. Nutt J.G., Burchiel K.J., Comella C.L., Jankovic J., Lang A.E., Laws E.R., et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003, 60(1):69-73.
159. Panganiban A.T., Fiore D. Ordered interstrand and intrastrand DNA transfer during reverse transcription. Science 1988, 241(4869):1064-1069.
160. Passini M.A., Bu J., Richards A.M., Treleaven C.M., Sullivan J.A., O'Riordan C.R., Cheng S.H. Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy. Human Gene Therapy 2014, 25(7):619-630. 10.1089/hum.2014.011.
161. Passini M.A., Dodge J.C., Bu J., Yang W., Zhao Q., Sondhi D., et al. Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis. Journal of Neuroscience 2006, 26(5):1334-1342. doi: 26/5/1334 [pii]10.1523/JNEUROSCI.2676-05.2006.
162. Perrin V., Regulier E., Abbas-Terki T., Hassig R., Brouillet E., Aebischer P., et al. Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease. Molecular Therapy 2007, 15(5):903-911.
163. Pickford F., Masliah E., Britschgi M., Lucin K., Narasimhan R., Jaeger P.A., et al. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. Journal of Clinical Investigation 2008, 118(6):2190-2199.
164. Poeppel P., Habetha M., Marcao A., Bussow H., Berna L., Gieselmann V. Missense mutations as a cause of metachromatic leukodystrophy. Degradation of arylsulfatase A in the endoplasmic reticulum. FEBS Journal 2005, 272(5):1179-1188.
165. Ralph G.S., Radcliffe P.A., Day D.M., Carthy J.M., Leroux M.A., Lee D.C., et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nature Medicine 2005, 11(4):429-433.
166. Raoul C., Abbas-Terki T., Bensadoun J.C., Guillot S., Haase G., Szulc J., et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nature Medicine 2005, 11(4):423-428. 10.1038/nm1207.
167. Regulier E., Pereira de Almeida L., Sommer B., Aebischer P., Deglon N. Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington's disease. Human Gene Therapy 2002, 13(16):1981-1990.
168. Rovelli A.M., Steward C.G. Hematopoietic cell transplantation activity in Europe for inherited metabolic diseases: open issues and future directions. Bone Marrow Transplant 2005, 35(Suppl 1):S23-S26.
169. Ruzo A., Marco S., Garcia M., Villacampa P., Ribera A., Ayuso E., et al. Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPSIIIA mice through systemic AAV9 gene transfer. Human Gene Therapy 2012, 23(12):1237-1246. [Research Support, Non-U.S. Govt.]. 10.1089/hum.2012.029.
170. Sacks O., Brown W.J., Aguilar M.J. Spongy degeneration of White matter: Canavan's Sclerosis. Neurology 1965, 15:165-171.
171. Sacramento D., Badrane H., Bourhy H., Tordo N. Molecular epidemiology of rabies virus in France: comparison with vaccine strains. Journal of General Virology 1992, 73(Pt 5):1149-1158.
172. Samaranch L., Salegio E.A., San Sebastian W., Kells A.P., Bringas J.R., Forsayeth J., et al. Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. Human Gene Therapy 2013, 24(5):526-532. [Research Support, N.I.H., Extramural]. 10.1089/hum.2013.005.
173. Samaranch L., Salegio E.A., San Sebastian W., Kells A.P., Foust K.D., Bringas J.R., et al. Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Human Gene Therapy 2012, 23(4):382-389. [Research Support, N.I.H., Extramural]. 10.1089/hum.2011.200.
174. Samaranch L., San Sebastian W., Kells A.P., Salegio E.A., Heller G., Bringas J.R., et al. AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction. Molecular Therapy 2014, 22(2):329-337. [Research Support, N.I.H., Extramural, Research Support, Non-U.S. Govt.]. 10.1038/mt.2013.266.
175. Sands M.S., Davidson B.L. Gene therapy for lysosomal storage diseases. Molecular Therapy 2006, 13(5):839-849.
176. Sapru M.K., Yates J.W., Hogan S., Jiang L., Halter J., Bohn M.C. Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Experimental Neurology 2006, 198(2):382-390.
177. Schapira A.H., Olanow C.W. Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. Annals of Neurology 2003, 53(Suppl 3):S149-S157. discussion S157-S149.
178. Schnepp B.C., Clark K.R., Klemanski D.L., Pacak C.A., Johnson P.R. Genetic fate of recombinant adeno-associated virus vector genomes in muscle. Journal of Virology 2003, 77(6):3495-3504. [Research Support, U.S. Govt., P.H.S.].
179. Sergijenko A., Langford-Smith A., Liao A.Y., Pickford C.E., McDermott J., Nowinski G., et al. Myeloid/Microglial driven autologous hematopoietic stem cell gene therapy corrects a neuronopathic lysosomal disease. Molecular Therapy 2013, 21(10):1938-1949.
180. Seymour L.W., Thrasher A.J. Gene therapy matures in the clinic. Nature Biotechnology 2012, 30(7):588-593.
181. Shoulson I. DATATOP: a decade of neuroprotective inquiry. Parkinson study group. Deprenyl and tocopherol antioxidative therapy of Parkinsonism. Annals of Neurology 1998, 44(3 Suppl 1):S160-S166.
182. Simola N., Morelli M., Pinna A. Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions. Current Pharmaceutical Design 2008, 14(15):1475-1489.
183. Snyder B.R., Gray S.J., Quach E.T., Huang J.W., Leung C.H., Samulski R.J., et al. Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery. Human Gene Therapy 2011, 22(9):1129-1135. [Comparative Study, Research Support, Non-U.S. Govt.]. 10.1089/hum.2011.008.
184. Sondhi D., Hackett N.R., Peterson D.A., Stratton J., Baad M., Travis K.M., et al. Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Molecular Therapy 2007, 15(3):481-491. 10.1038/sj.mt.6300049.
185. Sondhi D., Johnson L., Purpura K., Monette S., Souweidane M.M., Kaplitt M.G., et al. Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis. Human Gene Therapy Methods 2012, 23(5):324-335. [Research Support, N.I.H., Extramural]. 10.1089/hgtb.2012.120.
186. Sondhi D., Peterson D.A., Edelstein A.M., del Fierro K., Hackett N.R., Crystal R.G. Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis. Experimental Neurology 2008, 213(1):18-27. [Research Support, N.I.H., Extramural, Research Support, Non-U.S. Govt.]. 10.1016/j.expneurol.2008.04.022.
187. Sondhi D., Peterson D.A., Giannaris E.L., Sanders C.T., Mendez B.S., De B., et al. AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL. Gene Therapy 2005, 12(22):1618-1632. [Research Support, Non-U.S. Govt.]. 10.1038/sj.gt.3302549.
188. Souweidane M.M., Fraser J.F., Arkin L.M., Sondhi D., Hackett N.R., Kaminsky S.M., et al. Gene therapy for late infantile neuronal ceroid lipofuscinosis: neurosurgical considerations. Journal of Neurosurgery 2010, 6(2):115-122. [Clinical Trial, Phase I, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Govt.]. 10.3171/2010.4.PEDS09507.
189. Stewart H.J., Fong-Wong L., Strickland I., Chipchase D., Kelleher M., Stevenson L., et al. A stable producer cell line for the manufacture of a lentiviral vector for gene therapy of Parkinson's disease. Human Gene Therapy 2011, 22(3):357-369. 10.1089/hum.2010.142.
190. Stocking C., Bergholz U., Friel J., Klingler K., Wagener T., Starke C., et al. Distinct classes of factor-independent mutants can be isolated after retroviral mutagenesis of a human myeloid stem cell line. Growth Factors 1993, 8(3):197-209.
191. Storek B., Harder N.M., Banck M.S., Wang C., McCarty D.M., Janssen W.G., et al. Intrathecal long-term gene expression by self-complementary adeno-associated virus type 1 suitable for chronic pain studies in rats. Molecular Pain 2006, 2:4.
192. Tardieu M., Zerah M., Husson B., de Bournonville S., Deiva K., Adamsbaum C., Danos O. Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial. Human Gene Therapy 2014, 25(6):506-516. 10.1089/hum.2013.238.
193. Taylor D.L., Davies S.E., Obrenovitch T.P., Doheny M.H., Patsalos P.N., Clark J.B., et al. Investigation into the role of N-acetylaspartate in cerebral osmoregulation. Journal of Neurochemistry 1995, 65(1):275-281. [Comparative Study, Research Support, Non-U.S. Govt.].
194. Themis M., Waddington S.N., Schmidt M., von Kalle C., Wang Y., Al-Allaf F., et al. Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Molecular Therapy 2005, 12(4):763-771.
195. Towne C., Pertin M., Beggah A.T., Aebischer P., Decosterd I. Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery. Molecular Pain 2009, 5(1):52.
196. Traka M., Wollmann R.L., Cerda S.R., Dugas J., Barres B.A., Popko B. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS. Journal of Neuroscience 2008, 28(45):11537-11549. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Govt.]. 10.1523/JNEUROSCI.1490-08.2008.
197. Van Bogaert L., Bertrand I. Sur une idiote familiale avec degenerescence sponglieuse de neuraxe (note preliminaire). Acta Neurologica Belgica 1949, 49:572-587.
198. Vulchanova L., Schuster D.J., Belur L.R., Riedl M.S., Podetz-Pedersen K.M., Kitto K.F., et al. Differential adeno-associated virus mediated gene transfer to sensory neurons following intrathecal delivery by direct lumbar puncture. Molecular Pain 2010, 6:31. doi: 10. 1186/1744-8069-6-31.
199. Wachtel S.R., Bencsics C., Kang U.J. Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease. Journal of Neurochemistry 1997, 69(5):2055-2063.
200. Wang J., Leone P., Wu G., Francis J.S., Li H., Jain M.R., et al. Myelin lipid abnormalities in the aspartoacylase-deficient tremor rat. Neurochemical Research 2009, 34(1):138-148. 10.1007/s11064-008-9726-5.
201. Wong L.F., Azzouz M., Walmsley L.E., Askham Z., Wilkes F.J., Mitrophanous K.A., et al. Transduction patterns of pseudotyped lentiviral vectors in the nervous system. Molecular Therapy 2004, 9(1):101-111. doi: S152500160300337X.
202. Worgall S., Sondhi D., Hackett N.R., Kosofsky B., Kekatpure M.V., Neyzi N., et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Human Gene Therapy 2008, 19(5):463-474.
203. Wu Z., Asokan A., Samulski R.J. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Molecular Therapy 2006, 14(3):316-327.
204. Yanez-Munoz R.J., Balaggan K.S., MacNeil A., Howe S.J., Schmidt M., Smith A.J., et al. Effective gene therapy with nonintegrating lentiviral vectors. Nature Medicine 2006, 12(3):348-353. 10.1038/nm1365.
205. Yu H., Neimat J.S. The treatment of movement disorders by deep brain stimulation. Neurotherapeutics 2008, 5(1):26-36.
206. Zala D., Bensadoun J.C., Pereira de Almeida L., Leavitt B.R., Gutekunst C.A., Aebischer P., Deglon N. Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington's disease transgenic mice. Experimental Neurology 2004, 185(1):26-35.
207. Zeng B.J., Wang Z.H., Ribeiro L.A., Leone P., De Gasperi R., Kim S.J., et al. Identification and characterization of novel mutations of the aspartoacylase gene in non-Jewish patients with Canavan disease. Journal of Inherited Metabolic Disease 2002, 25(7):557-570. [Research Support, Non-U.S. Govt.].
208. Zennou V., Petit C., Guetard D., Nerhbass U., Montagnier L., Charneau P. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 2000, 101(2):173-185.
209. Zufferey R., Donello J.E., Trono D., Hope T.J. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. Journal of Virology 1999, 73(4):2886-2892.
210. Zufferey R., Dull T., Mandel R.J., Bukovsky A., Quiroz D., Naldini L., et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. Journal of Virology 1998, 72(12):9873-9880.
211. Zufferey R., Nagy D., Mandel R.J., Naldini L., Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nature Biotechnology 1997, 15(9):871-875.